The first drug pill for endometriosis has been approved for NHS use and provides hope that people in the UK suffer from weakness.
Relugolix-Estradiol-Norethisterone (also called relugolix combent therapy or ryeqo) is the first long-term daily pills permitted to treat endometriosis.
It shows significant developments in current treatment and provides patients with more convenient and potentially less difficult experiences.
This pill is expected to help patients with about 1,000 endometriosis every year.
It blocks certain hormones that contribute to endometriosis and provides the necessary hormone replacement at the same time. This dual motion alleviates the potential side effects and deals with the root cause of the condition.
Unlike existing injections that can worsen symptoms in the early stages, Ryeqo is taken at home, provides faster relief, and combines multiple hormones into a single pill. This does not require clinic visit often.
Endometriosis occurs when tissues similar to the uterine lining generally grow in the pelvis, bladder and intestines.
This condition can cause weak pain, heavy luck, fatigue and reproductive problems, which can have a big impact on women’s individuals and career life.
According to the National Institute for Health and Care Excellence (NIC), about 1.5 million people in the UK are suffering from endometriosis.
However, diagnosis usually takes nine years from the first time the symptoms appear. According to the NHS website, the symptoms can be similar to the symptoms associated with other conditions such as fibroids, pelvic inflammatory diseases and irritable bowel syndrome.
NICE first rejected this drug, but manufacturer Gedeon Richter provided new evidence to solve questions about the value of effects and money.
This drug will only be provided in NHS for patients with medical or surgical treatment for endometriosis.
Helen Knight, director of NICE’s pharmaceutical evaluation, said: “This new treatment shows potential changes in how we manage endometriosis, and returns control of the patient’s hands while ensuring the value of taxpayers.
“Instead of traveling with a clinic for injections, there is a daily tablet that can be taken at home.
“Treatment can also stop and start more easily, which is especially important for managing side effects with people who plan children.
“This convenience not only helps patients, but also reduces pressure on NHS services.”
The list price of treatment is £ 72 for 28 days (excluding VAT).
